Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

BAA – Medical Countermeasures for Priority Pathogens

by Global Biodefense Staff
July 16, 2015
NIAID Priority Pathogen Countermeasures

The National Institute of Allergy and Infectious Diseases (NIAID) has released a new Broad Agency Announcement (BAA) to support development of therapeutic products for use in post-event settings following the intentional release or natural outbreak of high priority biological threats.

Countermeasures are sought for Ebola and other filoviruses, Clostridium botulinum, Yersinia pestis, Francisella tularensis, Burkholderia pseudomallei and other disease-causing agents from the NIAID Category A, B, or C Priority Pathogen list.

This BAA focuses on the development of promising lead therapeutic candidates/products which have demonstrated feasibility of manufacturing, in vitro and in vivo evidence of efficacy, and sufficient characterization to allow the development of a draft target product profile.

Of particular interest are countermeasures broad spectrum therapeutic activity against viruses or bacterial pathogens. This approach would allow a small number of drugs to replace dozens of pathogen-specific drugs for emergency use.

Additionally, strategies to overcome bacterial and viral drug resistance could extend the clinical utility of existing broad spectrum anti-infectives and have immediate benefits.

For these reasons, non-traditional therapeutics are encouraged provided they have demonstrated therapeutic activity when used alone or in combination with an existing licensed product. Therapeutic activity is defined as the cure or mitigation of disease once signs and symptoms of infection are evident.

The solicitation also focuses on supporting development of promising anti-toxins as therapeutic products, particularly small molecule therapeutics with anti-toxin activity.

Further details are available Solicitation Number: BAA-NIAID-DMID-NIH-AI-2015037. The response deadline is Aug 31, 2015.

Tags: AnthraxAntimicrobialsAntitoxinsAntiviralsBAABotulinum NeurotoxinBurkholderiaEbolaF. tularensisMarburgNIAIDVaccines

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC